Logo Logo Logo Logo Logo
  • About
    • Board & Management
    • Business Development
  • Diagnostic Areas
    • COVID-19
    • Intelligent Innovation
  • Products & Solutions
    • Near-patient Workflow Solutions
  • News
  • Investors
    • Year in Review 2021
    • Corporate Calendar
    • Financial Reports
    • Leadership
    • General Meetings
    • Other Regulated Information
    • Advisor and Investor Contacts
    • AIM Rule 26 information
    • Corporate Governance
  • Our People
    • Careers
  • Contact
  • English
  • About
    • Board & Management
    • Business Development
  • Diagnostic Areas
    • COVID-19
    • Intelligent Innovation
  • Products & Solutions
    • Near-patient Workflow Solutions
  • News
  • Investors
    • Year in Review 2021
    • Corporate Calendar
    • Financial Reports
    • Leadership
    • General Meetings
    • Other Regulated Information
    • Advisor and Investor Contacts
    • AIM Rule 26 information
    • Corporate Governance
  • Our People
    • Careers
  • Contact
  • English
Search:

01 Dec Liquidity Agreement Monthly Update and Total Voting Rights

Posted at 07:19h in Uncategorized

Liquidity Agreement -1 December Paris, France and Cambridge, UK – 1 December 2017 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update...

Read More

07 Nov FOR THE SECOND YEAR RUNNING NOVACYT WINS TECHNOLOGY FAST 50 AWARD

Posted at 07:00h in Board, Novacyt Group, Products

Novacyt Technology Fast 50 Award 2017 ENG Paris, France and Cambridge, UK – 7 November 2017 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces...

Read More

02 Nov SETTLEMENT AND REDEMPTION OF ALL OUTSTANDING YORKVILLE CONVERTIBLE BONDS

Posted at 09:11h in Uncategorized

Settlement and redemption of convertible bonds with Yorkville ENG Removes potentially dilutive instrument Strengthened balance sheet supports future growth...

Read More

01 Nov ADMISSION AND FIRST DAY OF DEALINGS ON AIM

Posted at 07:00h in Products, Products, Products, Products, Products, Products, Products

Novacyt admission and first day of dealings AIM ENG Paris, France and Cambridge, UK – 1st November 2017 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,...

Read More

18 Oct PROPOSED ADMISSION TO TRADING ON AIM AND SUCCESSFUL CONDITIONAL CAPITAL RAISE OF €9.7 MILLION

Posted at 07:00h in Board, Novacyt Group, Products

Novacyt proposed admission to AIM ENG Paris, France and Cambridge, UK – 18th October 2017 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces that it has raised...

Read More

03 Oct NOVACYT STRENGTHENS PRIMERDESIGN BUSINESS WITH NEW SENIOR HIRE

Posted at 07:00h in Board, Board, Board, Board, Board, Board, Board

Novacyt Senior Hire for PrimerDesign PR Eng Paul Eros joins as Commercial Director, completing investment in the Group’s senior leadership team  ...

Read More

04 Sep Novacyt announces further progress in China

Posted at 07:08h in Uncategorized

Novacyt announces largest order in China PR ENG Largest order in China for Primerdesign q16 instruments NOVAprep® demand growing  ...

Read More

16 Aug NOVACYT HALF YEAR 2017 RESULTS Consolidated sales growth +53% CER Group continues positive outlook for 2017

Posted at 07:07h in Board, Novacyt Group, Products

Novacyt half year 2017 results ENG Paris, France and Cambridge, UK – 16th August 2017 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces unaudited reviewed financial results...

Read More

20 Jul NOVACYT REVENUES HALF YEAR 2017 Consolidated sales growth +53% CER Group continues positive outlook for 2017

Posted at 16:47h in Novacyt Group, Novacyt Group, Novacyt Group, Novacyt Group, Novacyt Group, Novacyt Group, Novacyt Group

Novacyt revenues half year 2017 ENGLISH Paris, France and Cambridge, UK – 20th July 2017 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces its unaudited revenues for...

Read More

20 Jun NOVACYT SUCCESSFULLY COMPLETES €3.0M FUNDRAISING

Posted at 07:00h in Uncategorized

Novacyt Financing PR ENG (20-06-17) FINAL Momentum towards profitability continues through H1 2017 Investing to support increased sales demand across business...

Read More
  • 1
  • 2

About


Novacyt is a leading global diagnostics company. We protect people and society in the fight against infectious diseases.

Company


Unit 1, Watchmoor Point, Watchmoor Road, Camberley, Surrey, GU15 3AD, UK

Novacyt UK Holdings - 12031776
Novacyt SA - 491062527

Latest reports


Investor Presentation April 2022
Year in Review 2021

© 2022 Novacyt | Privacy Policy | Copyright | Terms & Conditions

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT